UBE2S emerges as a key driver in an NK cell–based prognostic model for clear cell renal cell carcinoma
PLOS One · 14.05.2026 · 21 (5) · e0344925
DOI: 10.1371/journal.pone.0344925 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 14.05.2026. Verfasst von Kang Leng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Killer Cells, Natural, Ubiquitin-Conjugating Enzymes, Kidney Neoplasms. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health of Shandong Province.
Abstract (Originalsprache)
Background
Clear cell renal cell carcinoma (ccRCC) is highly heterogeneous, and robust biomarkers for risk stratification and therapeutic guidance remain limited.
Methods
We integrated single-cell RNA sequencing (scRNA-seq) of tumor and adjacent tissues with multi-cohort transcriptomic validation. High-dimensional weighted gene co-expression network analysis (hdWGCNA) was applied to identify pathogenic immune subsets and candidate genes. Prognostic modeling was performed using CoxBoost, and UBE2S function was validated by in vitro knockdown assays. Results scRNA-seq revealed extensive remodeling of the tumor microenvironment, highlighting NK cell subpopulations with strong intercellular signaling. hdWGCNA identified 12 core genes enriched in protein processing and MAPK pathways, with UBE2S emerging as the top driver. A CoxBoost-based 12-gene signature demonstrated robust predictive accuracy across independent datasets. Functionally, UBE2S knockdown suppressed ccRCC cell proliferation and migration, while immune correlation analyses linked UBE2S to altered tumor immunogenicity and genomic stability.
Conclusions
Our study identifies NK cell subsets and UBE2S as key contributors to ccRCC progression and establishes a clinically relevant 12-gene prognostic model, offering potential targets for precision therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Urology, The 960th Hospital of the PLA Joint Logistics Support Force, Jinan, China.
- Department of Intensive Care Unit, Jinan Fourth People's Hospital Affiliated to Shandong Second Medical University, Jinan, China.
ORCID-Profile: Kang Leng
Förderung
- Department of Health of Shandong Province
Zitieren
APA
Leng, K., Zhou, Y., Zhao, J., Wang, X., & Song, H. (2026). UBE2S emerges as a key driver in an NK cell–based prognostic model for clear cell renal cell carcinoma. PLOS One, 21(5), e0344925. https://doi.org/10.1371/journal.pone.0344925
Vancouver
Leng K, Zhou Y, Zhao J, Wang X, Song H. UBE2S emerges as a key driver in an NK cell–based prognostic model for clear cell renal cell carcinoma. PLOS One. 2026;21(5):e0344925. doi:10.1371/journal.pone.0344925
BibTeX
@article{Leng2026,
author = {Leng, Kang and Zhou, Yiheng and Zhao, Jian and Wang, Xiaoguang and Song, Hua},
title = {UBE2S emerges as a key driver in an NK cell–based prognostic model for clear cell renal cell carcinoma},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {5},
pages = {e0344925},
doi = {10.1371/journal.pone.0344925}
}
EUVIMED